Abstract Background/Introduction Psoriatic disease is associated with impaired endothelial and vascular function. Purpose We investigated whether intervention with Endocalyx (Microvascular Health Solutions),a dietary supplement containing glycosaminoglycans and fucoidan, can improve endothelial glycocalyx integrity and arterial stiffness in patients with psoriatic disease. Methods Thirty patients with psoriatic disease were randomized to receive Endocalyx (n=15) or placebo (n=15) for 4 months. We measured at baseline and at 4 months of treatment: a)perfused boundary region(PBR) of the sublingual microvessels with a lumen diameter ranging from 4 to 25 μm, as a marker of endothelial glycocalyx integrity and b)carotid-femoral pulse wave velocity (PWV - Complior SP ALAM) and augmentation index (AI). Results Four months after treatment, patients under Endocalyx showed a significant reduction of PBR 4-25μm (2.10±0.31 vs. 2.31±0.20μm), PBR 10-19 μm (2.41±0.43 vs. 2.54±0.31μm), PBR 20-25 μm (2.62±0.42 vs. 3.02±0.30μm), PWV (9.4±1.8 vs. 10.4±2.2m/s) and AI[-4 (-39 – 16) vs. 9.8 (-8 – 23) %] (p<0.05 for all comparisons).No significant changes in the aforementioned markers were observed in placebo group (p>0.05; Table). In patients who were treated with Endocalyx, the percentage reduction of PBR 4-25μm was associated with the corresponding decrease of PWV (r=0.39, p=0.032) and with the improvement of AI (r=0.48, p=0.024) at 4 months. Conclusions Four-month treatment with Endocalyx may improve endothelial glycocalyx integrity and vascular function in patients with psoriatic disease.
Read full abstract